Recent Updates
Recently added Catalysts
AMRX Positive Sentiment

Amneal to Report Second Quarter 2026 Results on July 30, 2026

Key Takeaway: Amneal Pharmaceuticals, Inc. has announced it will report its second quarter 2026 financial results on July 30, 2026, before the market opens. The company will host an audio webcast at 8:30 a.m. ET for investors. Interested parties can register for the webcast through the company's Investor Relations website.
Price reaction · baseline $17.02 (2026-07-09 close) · hit after-hours · clean, no other AMRX news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Amneal is expanding access to affordable medicines.
  • The company has a diverse portfolio of approximately 300 medicines.
  • Amneal's financial results announcement indicates transparency and engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
3.6%
average across 12 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Mometasone Furoate
Phase 3 · Seasonal Allergic Rhinitis

Full Press Release Details

BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be available through the Investor Relations section of the Company's website atinvestors.amneal.com. Individuals may register for the webcast by clickinghere. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbershere. The access code for is 901153095. A replay of the webcast will be available shortly after the call.
About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit  and follow us onLinkedIn.

Investor ContactAnthony DiMeoVP, Investor Relationsanthony.dimeo@amneal.com

Frequently Asked Questions

When will Amneal report its Q2 2026 results?

Amneal will report its Q2 2026 financial results on July 30, 2026.

What time is the Amneal earnings call?

The Amneal earnings call is scheduled for 8:30 a.m. ET.

How can I access the Amneal webcast?

The webcast can be accessed through the Investor Relations section of Amneal's website.

Who should I contact for investor inquiries at Amneal?

For investor inquiries, contact Anthony DiMeo, VP of Investor Relations.

Last updated: Jul 9, 2026